REG - Faron Pharma. Oy - Decisions of the Board of Directors

Faron Pharmaceuticals OyAnnouncement

08/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5914Ja&default-theme=true

RNS Number : 5914J  Faron Pharmaceuticals Oy  08 April 2024

Faron Pharmaceuticals Oy

("Faron or the "Company")

Decisions of the Board of Directors

Company announcement, April 8, 2024 at 9:05 (EEST) / 7:05 AM (GMT) / 12:05 AM
(EDT)

TURKU, FINLAND / BOSTON, MA - The annual general meeting ("AGM") of Faron
Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place on April 5,
2024 and after the AGM, the Board of Directors ("Board") convened.

 

Frank Armstrong and Erik Ostrowsi did not stand for re-election and thus their
tenure in the Company Board of Directors ended at the end of the AGM on 5
April, 2024.

 

At the meeting of the Board held following the AGM, Tuomo Pätsi was elected
as the Chair of the Board.

 

In addition, the Board elected the Chairs and other members to the Board
committees from among its members as follows:

·    Markku Jalkanen was elected the Chair of the Audit Committee and
Marie-Louise Fjällskog and John Poulos were elected as members of the Audit
Committee.

·    Tuomo Pätsi was elected the Chair of the Nomination Committee and
Markku Jalkanen and Christine Roth were elected as the other members of the
Nomination Committee.

·    John Poulos was elected as the Chair of the Remuneration Committee
and Tuomo Pätsi and Christine Roth were elected as the other members of the
Remuneration Committee.

·    John Poulos was elected as the Chair of the Business Development
Committee and Markku Jalkanen and Juho Jalkanen were elected as the other
members of the Business Development Committee

For more information please contact:

Faron Pharmaceuticals

 

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com (mailto:daniel@lifesciadvisors.com)

+1 (617) 430-7576

 

ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com (mailto:faron@consilium-comms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

 

About Faron Pharmaceuticals Oy

 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments treatments and as a monotherapy in last line solid
cancers. Further information is available at www.faron.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUBURRSKUSRUR